Sandu Pharmaceuticals Ltd.
BSE: SANDUPHQ · Pharmaceuticals · sector
₹34.70BSE close 2026-10-26
Key numbers
Market cap₹34 cr
Price₹34.70
52w high / low₹50 / ₹30
P/E17.7xSector median 27.9x
P/B0.8xSector median 2.9x
Book value₹45.2
Dividend yield2.30%Sector median 0.48%
ROE4.1%Sector median 11.7%
ROCE6.3%Sector median 12.3%
OPM4.3%Sector median 14.0%
Debt / equity0.01xSector median 0.16x
EV/EBITDA9.0xSector median 18.6x
Interest cover24.2x
Current ratio2.43x
Sales growth 3y+2.3%Sector median +9.6%
Profit growth 3y+5.1%Sector median +13.3%
PEG4.27x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹7 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 24.2x in the last 12 months.
- Other income was 25% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹34.70 on 2026-10-26: -30.6% from the 52-week high, +15.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹62.26 · low ₹33.01
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 14 | 17 | 18 | 19 | 17 | 16 |
| EBITDA | 0 | 1 | 1 | 1 | 1 | 1 |
| OPM % | 3.2% | 3.2% | 4.9% | 5.5% | 3.4% | 3.3% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 1 | 1 | 0 | 0 |
| EPS (₹) | 0.34 | 0.23 | 0.54 | 1.01 | 0.04 | 0.37 |
| Revenue YoY | +19.8% | -1.9% | ||||
| Profit YoY | -87.9% | +4.5% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 66 | 65 | 67 | 67 | 70 | 70 |
| EBITDA | 3 | 2 | 2 | 3 | 3 | 3 |
| Net profit | 2 | 2 | 1 | 2 | 2 | 2 |
| EPS (₹) | 1.99 | 1.62 | 1.51 | 1.60 | 1.83 | 1.96 |
| Revenue growth | -0.2% | +3.0% | -0.1% | +4.1% | – | |
| Profit growth | -4.4% | -3.9% | +6.2% | +14.2% | – | |
| Dividend / share (₹) | – | 0.75 | 0.75 | 0.80 | 0.80 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +2.3% | – | – |
| Net profit | +5.1% | – | – |
| EPS | +4.1% | – | – |
| Share price | – | -23.5% (2y) | -25.7% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 42 | 44 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 3 | 7 |
| Total assets | 56 | 56 |
| Fixed assets | 8 | 9 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 12 |
| Receivables | 5 | 5 |
| Inventory | 14 | 10 |
| Payables | 4 | 4 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 1 | 6 |
| Cash from investing | -0 | -1 |
| Cash from financing | -0 | -1 |
| Capex | 1 | 1 |
| Free cash flow | 0 | 5 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 3.7% | 4.0% |
| ROCE % | 5.4% | 6.3% |
| Debtor days | 26 | 28 |
| Inventory days | 161 | 121 |
| Payable days | 51 | 52 |
| Cash conversion cycle (days) | 136 | 97 |
| Working capital days | 77 | 78 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| SANDUPHQ | ₹34 cr | 17.7x | 0.8x | 4.1% | 6.3% | 4.3% | +2.3% | 2.30% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-04 | Dividend | Final Dividend Rs 1.0 |
| 2025-09-18 | Dividend | Final Dividend Rs 0.8 |
| 2024-09-19 | Dividend | Final Dividend Rs 0.8 |
| 2023-09-18 | Dividend | Final Dividend Rs 0.75 |
| 2022-09-23 | Dividend | Dividend Rs 0.75 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | SANDUPHQ |
| BSE code | 524703 |
| ISIN | INE751D01014 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.